Gastroesophageal Reflux Disease

Disease

Also known as: GERD

Related News

Cinclus Pharma Completes Screening in Phase III HEEALING1 Trial of Linaprazan Glurate

Jun 19, 2026

Cinclus Pharma has completed screening for the pivotal Phase III HEEALING1 trial of linaprazan glurate in erosive GERD, with topline results expected in Q4 2026. Phase II data showed up to 93% healing at four weeks versus 38% for lansoprazole. The company also provided updates on its Phase I safety study and financial position.

Cinclus Pharma says Phase III study is nearing full enrollment

May 20, 2026

Cinclus Pharma said its first Phase III study is nearing full enrollment, with topline results expected in the fourth quarter of 2026. The company also reported regulatory progress for linaprazan glurate and a EUR 28 million financing agreement.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07797959	Thread-Embedding Acupuncture as an Adjunct to Proton Pump Inhibitor Therapy for Gastroesophageal Reflux Disease	RECRUITING	NA